The effect of etiology on efficacy in HCC patients receiving anti-PD-1 treatment remains unclear, despite the fact that the efficacy of nivolumab and pembrolizumab was not affected by HBV or HCV infection in sorafenib-treated patients in phase 1/2 trials [8, 21, 22]. Here, PDCD1 is linked to hepatocellular carcinoma.